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Background: The preventive effects of histamine 2 receptor antagonists vs. proton pump inhibitors on low-dose
aspirin (LDA)-related gastroduodenal mucosal injury have not been fully investigated. We conducted a cross-
sectional study to compare the prevalence of gastroduodenal ulcers or erosions in patients taking LDA with either
40 mg/day of famotidine or 15 mg/day of lansoprazole for at least three months.
Methods: Of 84 eligible patients, two taking 40 mg/day of famotidine and four taking 15 mg/day of lansoprazole
refused to undergo upper gastrointestinal endoscopy. Ultimately, we performed upper gastrointestinal endoscopy
in 78 patients taking either 40 mg/day of famotidine (group F, n = 31) or 15 mg/day of lansoprazole (group L,
n = 47). The prevalence of gastroduodenal ulcers or erosions and the magnitude of gastric mucosal injury evaluated
using modified Lanza scores were compared between the two groups.
Results: No patients in either group had gastroduodenal ulcers. Gastroduodenal erosions were more prevalent in
group F than in group L (48.4% vs. 17.0%, p = 0.005). The modified Lanza scores (mean ± SD) were significantly
higher in group F than in group L (0.9 ± 1.3 vs. 0.3 ± 0.7, p = 0.007). A multivariate logistic regression analysis
showed that the use of lansoprazole was negatively associated with gastroduodenal erosions.
Conclusions: This study suggests that 15 mg/day of lansoprazole may be more effective in preventing the
development of LDA-related gastroduodenal erosions than 40 mg/day of famotidine. The preventive effects of
these two regimens on the development of LDA-related gastroduodenal ulcers require further investigation.
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Low-dose aspirin (LDA) (75 – 325 mg/day), which is
widely used for the primary and secondary prevention of
cardiovascular events and the prevention of coronary
stent thrombosis [1,2], is associated with a 2- to 4-fold
increased risk of upper gastrointestinal complications,
such as gastroduodenal ulcers and bleeding [3,4]. There-
fore, it is clinically important to prevent gastroduodenal
mucosal injury in patients talking LDA. Proton pump
inhibitors (PPIs) are considered to be the preferred
agents for prophylaxis of LDA-related gastroduodenal* Correspondence: akira@oita-u.ac.jp
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reproduction in any medium, provided the ormucosal injury [5]. Famotidine, a histamine 2 receptor
antagonist (H2RA), has also been reported to suppress
the development of LDA-related gastroduodenal ulcers
[6]. One prospective, randomized, comparative study [7]
examined the effects of H2RAs vs. PPIs on the primary
prevention of LDA-related gastric mucosal injury and
showed that 15 mg/day of lansoprazole is more effective
in preventing LDA-related gastric mucosal injury than
40 mg/day of famotidine. However, in that study, the
duration of treatment was only seven days. Another pro-
spective, randomized, comparative study [8] examined
the effects of H2RAs vs. PPIs on the secondary preven-
tion of LDA-related dyspeptic or bleeding gastroduode-
nal ulcers and erosions and showed that 80 mg/day ofLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Modified Lanza scores
Score Findings
0 No hemorrhage or erosions observed
1 One or two hemorrhages or erosions observed in one gastric
area
2 Three to five hemorrhages or erosions observed in one gastric
area
3 Hemorrhages or erosions observed in two gastric areas or six or
more hemorrhages or erosions observed in one gastric area, with
the total number not exceeding 10 in the entire stomach
4 Hemorrhages or erosions observed in three or more gastric areas
or 11 or more hemorrhages or erosions observed in the entire
stomach
5 Gastric ulcers
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the secondary prevention of recurrent dyspeptic or
bleeding gastroduodenal ulcers and erosions. However,
in that study, follow-up endoscopic examinations were
performed only in patients with dyspepsia or bleeding
(melena or hematemesis). It is well known that LDA-
related gastroduodenal mucosal injury is often asymp-
tomatic [9,10]. Therefore, whether there are distinct
differences in the effects of H2RAs vs. PPIs on the
primary and secondary prevention of LDA-related gas-
troduodenal mucosal injury has not been fully clarified.
We previously demonstrated that PPIs, but not H2RAs,
are negatively and independently associated with gastro-
duodenal ulcers or erosions in asymptomatic patients
taking LDA [11]. In the present study, we compared the
prevalence of gastroduodenal ulcers or erosions in
patients taking LDA with either 40 mg/day of famotidine
or 15 mg/day of lansoprazole for at least three months.
Methods
This cross-sectional study was conducted between April
2011 and June 2012 at Oita University Hospital in
accordance with the Declaration of Helsinki and its
amendments. The study protocol was approved by the
ethics committee of Oita University Hospital, and writ-
ten informed consent was obtained from all patients
before enrollment.
Study population
Eligible inpatients or outpatients of the Cardiology Division
of Oita University Hospital who were taking LDA with
either 40 mg/day of famotidine or 15 mg/day of
lansoprazole for at least three months were prospect-
ively enrolled in this study, unrelated to the presence or
absence of gastrointestinal symptoms. The inclusion
criteria were as follows: age > 20 years; no history of
surgery for esophageal, gastric or duodenal diseases;
neither known gastrointestinal bleeding nor gastroduo-
denal ulcers within the previous 12 months; neither
acute coronary syndrome nor stroke within the previ-
ous three months; an absence of severe chronic heart fail-
ure (New York Heart Association functional class IV); a
lack of use of steroids or nonsteroidal anti-inflammatory
drugs; and an absence of malignant diseases.
Data collection
The following demographic data were collected: age,
gender, body mass index, the presence or absence of
current smoking, daily alcohol drinking (unrelated to the
amount of alcohol), hypertension, dyslipidemia and dia-
betes mellitus, a history of cardiovascular disease, gastro-
duodenal ulcers or eradication of Helicobacter pylori
(H. pylori), gastrointestinal symptoms, the H. pylori infec-
tion status and current medications. Current smoking wasdefined as daily or non-daily smoking at the time of
study entry. Hypertension was defined as a systolic blood
pressure ≥140 mmHg, a diastolic blood pressure ≥90 mmHg
or treatment with antihypertensive medications. Dysli-
pidemia was defined as a serum low-density lipoprotein
cholesterol level ≥140 mg/dl, a high-density lipoprotein
cholesterol level <40 mg/dl, a triglyceride level ≥150 mg/dl
or treatment with lipid-lowering drugs. Diabetes mellitus
was defined as a fasting plasma glucose level ≥126 mg/dl,
a plasma glucose level ≥200 mg/dl at two hours after a 75-
g glucose load or treatment with hypoglycemic agents.
Gastrointestinal symptoms (reflux, abdominal pain and
indigestion) were evaluated using the gastrointestinal
symptom rating scale [12] immediately before esopha-
gogastroduodenal endoscopy. The presence or absence of
H. pylori infection was examined using a urine-based
enzyme-linked immunosorbent assay (Otsuka Pharma-
ceutical, Tokyo, Japan) [13,14].
Endoscopic examinations
Esophagogastroduodenal endoscopy was performed with-
out cessation of LDA. An ulcer was defined as a mucosal
defect having a significant depth, measuring at least 3 mm
over its longest diameter. An erosion was defined as a
mucosal defect measuring less than 3 mm. The magni-
tude of gastric mucosal injury was assessed using the
modified Lanza score [15] (Table 1). The evaluations
were conducted by experienced endoscopists who were
blinded to all clinical data.
Statistical analysis
Continuous data are expressed as the mean ± SD. Com-
parisons of continuous variables between two groups were
made using the unpaired t-test or the Mann–Whitney
U-test. Comparisons of categorical variables between
two groups were made using the Fisher’s exact test or
the chi-square test. A multivariate logistic regression
analysis was performed to determine whether the use of
15 mg/day of lansoprazole was independently associated
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sidered to be statistically significant. All analyses were
performed using the IBM SPSS Statistics 20 software pack-
age (International Business Machines Corp., New York,
USA).
Results
Between April 2011 and June 2012, there were 84
eligible patients taking LDA with either 40 mg/day of
famotidine or 15 mg/day of lansoprazole for at least
three months. Of the 84 patients, two taking 40 mg/day
of famotidine and four taking 15 mg/day of lansoprazole
refused to undergo upper gastrointestinal endoscopy.
Ultimately, 78 patients taking LDA with either 40 mg/day
of famotidine (group F, n = 31) or 15 mg/day of lanso-
prazole (group L, n = 47) for at least three months were
enrolled in the present study (Figure 1).
The patient characteristics are shown in Table 2. There
were no significant differences in patient characteristics
between the two groups.
No patients had gastroduodenal ulcers. Gastroduode-
nal erosions were more prevalent in group F than in
group L (48.4% vs. 17.0%, p = 0.005) (Figure 2).
The modified Lanza scores (mean ± SD) were signifi-
cantly higher in group F than in group L (0.9 ± 1.3 vs.
0.3 ± 0.7, p = 0.007). After adjusting for confounding
factors, including age, male gender, body mass index,
current smoking, daily alcohol drinking, a history of
gastroduodenal ulcers and positive urinary H. pylori
antibodies, the use of lansoprazole was found to be
negatively associated with gastroduodenal erosions (odds
ratio 0.18, 95% confidence interval 0.06-0.59, p = 0.005).
Discussion
Primary findings
The primary findings of the present study are as follows:
(1) gastroduodenal erosions were less prevalent in patients84 eligible patients 
• Taking low-dose aspirin  with either 40 mg/day of fa
3 months 
• Age >20 years 
• No history of surgery for esophageal, gastric or duo
• Neither known gastroduodenal bleeding nor gastrod
• Neither acute coronary syndrome nor stroke with th
• Absence of severe heart failure (New York Heart As
• No use of steroids or non-steroidal anti-inflammator
• No malignant diseases  
31 with famotidine use and 47 with lansoprazole u
Figure 1 Flow chart of the study cohort.taking LDA with 15 mg/day of lansoprazole than in those
taking LDA with 40 mg/day of famotidine; (2) no patients
in either group had gastroduodenal ulcers; and (3) the
multivariate logistic regression analysis showed that the
use of 15 mg/day of lansoprazole was negatively associated
with gastroduodenal erosions.
Previous studies
Although PPIs are considered to be the preferred agents
for prophylaxis of LDA-related gastroduodenal mucosal
injury [5], there are only two prospective, randomized,
comparative studies examining the effects of H2RAs vs.
PPIs on the prevention of LDA-related gastric mucosal
injury [7,8]. Nishio et al. [7] randomly administered
100 mg/day of aspirin, 100 mg/day of aspirin plus
40 mg/day of famotidine or 100 mg/day of aspirin plus
15 mg/day of lansoprazole for seven days in a crossover
fashion in 15H. pylori-negative healthy volunteers and
compared the magnitude of gastric mucosal injury
among the three regimens using modified Lanza scores.
The results showed that the modified Lanza scores were
significantly lower in the 100 mg/day of aspirin plus
15 mg/day of lansoprazole group than in the other two
groups, suggesting that 15 mg/day of lansoprazole may
be more effective in preventing LDA-related gastric mu-
cosal injury than 40 mg/day of famotidine. However, in
that study, the subjects were H. pylori-negative healthy
young volunteers, and the duration of treatment was
only seven days. Ng et al. [8] compared the recurrence
rate of LDA-related dyspeptic or bleeding gastroduode-
nal ulcers and erosions occurring within 48 weeks
between 65 patients receiving famotidine (80 mg/
day) treatment and 65 patients receiving pantoprazole
(20 mg/day) treatment and showed that the recurrence
rate of dyspeptic or bleeding gastroduodenal ulcers and
erosions was lower in the latter group than in the former
group (0% vs. 9.2%, p = 0.03). However, in that study,motidine or 15 mg/day of lansoprazole for at least 
denal diseases 
uodenal ulcers within the previous 12 months 
e previous 3 months 
sociation functional class IV) 
y drugs 
6 patients (2 with famotidine use and 4 
with lansoprazole use) refused to 
undergo upper gastrointestinal
endoscopy. 
se were enrolled in this cross-sectional study. 






Age (years) 72.0 ± 9.3 74.6 ± 8.8 0.22
Male 26 (83.9%) 32 (68.1%) 0.19
Body mass index (kg/m2) 23.8 ± 3.4 24.3 ± 3.6 0.50
Hypertension 25 (80.6%) 44 (93.6%) 0.14
Diabetes mellitus 9 (29.0%) 18 (38.3%) 0.47
Current smoking 0 (0%) 2 (4.3%) 0.52
Daily alcohol drinking 12 (38.7%) 13 (27.7%) 0.33
Coronary artery disease 26 (83.9%) 43 (91.5%) 0.47
Prior percutaneous coronary
intervention
25 (80.6%) 39 (83.0%) 1.0
Prior coronary bypass surgery 1 (3.2%) 2 (4.3%) 1.0
Prior stroke 4 (12.9%) 4 (8.5%) 0.71
Atrial fibrillation 6 (19.4%) 7 (14.9%) 0.76
History of gastroduodenal ulcer 5 (16.1%) 9 (19.1%) 0.77
History of eradication of H. pylori 3 (9.7%) 5 (10.6%) 1.0
Gastrointestinal symptom rating
scale
Reflux symptom score 1.4 ± 0.6 1.3 ± 0.6 0.19
Abdominal pain score 1.4 ± 0.7 1.2 ± 0.5 0.32
Indigestion score 1.4 ± 0.6 1.6 ± 0.6 0.24
Positive urinary H. pylori antibodies 15 (48.4%) 22 (46.8%) 1.0
Duration of lansoprazole or
famotidine treatment
0.76
<1 year 7 (14.9%) 6 (19.4%)
≥1 year(s) 40 (85.1%) 25 (80.6%)
Dose of aspirin 1.0
81 mg/day 1 (3.2%) 2 (4.3%)
100 mg/day 30 (96.8%) 45 (95.7%)
Type of aspirin 1.0
Enteric-coated formulation 30 (96.8%) 45 (95.7%)
Buffered formulation 1 (3.2%) 2 (4.3%)
Other antiplatelet agents 12 (38.7%) 17 (36.2%) 1.0
Warfarin 8 (25.8%) 8 (17.0%) 0.40
Dabigatran 2 (7.4%) 2 (4.3%) 0.62
Nitrates 10 (32.3%) 16 (34.0%) 1.0
Calcium antagonists 14 (45.2%) 26 (55.3%) 0.49
Angiotensin-converting enzyme
inhibitors
3 (9.7%) 4 (8.5%) 1.0
Angiotensin receptor blockers 14 (45.2%) 30 (63.8%) 0.16
Statins 27 (87.1%) 42 (89.4%) 1.0













Group F (n=31) Group L (n=47)
gastroduodenal erosions gastric erosions duodenal erosions
p=0.005 
Figure 2 Comparison of the prevalence of gastroduodenal
erosions between patients taking 40 mg/day of famotidine
(group F) and those taking 15 mg/day of lansoprazole (group L).
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in patients with dyspepsia or bleeding (melena or hema-
temesis). Therefore, the exact effects of H2RAs vs. PPIs
on the primary and secondary prevention of LDA-related gastroduodenal mucosal injury have not been
fully clarified.
The present study
In the present study, we compared the prevalence of
gastroduodenal ulcers or erosions in patients taking
LDA with either 40 mg/day of famotidine or 15 mg/day
of lansoprazole for at least three months and found that
gastroduodenal erosions were less prevalent in patients
taking LDA with 15 mg/day of lansoprazole than in
those taking LDA with 40 mg/day of famotidine. This
result suggests that 15 mg/day of lansoprazole may be
more effective in preventing the development of LDA-
related gastroduodenal erosions than 40 mg/day of
famotidine. Gastroduodenal erosions are the most readily
observable finding of initial gastroduodenal mucosal
injury following aspirin administration [16]. Gastric acid
plays an important role in the development of LDA-
related gastroduodenal mucosal injury, and the severity of
LDA-related gastric mucosal injury is associated with gas-
tric acidity [7,17]. Because PPIs are more effective in sup-
pressing the secretion of gastric acid than H2RAs
[7,17,18], the findings of the present study are reasonable.
However, it should be noted that, in the present study, the
mean modified Lanza score among the patients taking
40 mg/day of famotidine was low and that the difference
in the scores between the two groups was small. In the
present study, none of the patients taking either
40 mg/day of famotidine or 15 mg/day of lansoprazole
had gastroduodenal ulcers. Yeomans et al. [10] reported
that gastroduodenal ulcers were observed in 10.7% of 187
patients taking LDA without gastroprotective medications.
In the OBERON trial, which compared the occurrence of
peptic ulcers over 26 weeks among patients taking LDA
with those taking a placebo, 20 mg/day of esomeprazole
or 40 mg/day of esomeprazole, peptic ulcers developed in
7.4% of 805 placebo recipients (an intention-to-treat
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the patients had no history of gastroduodenal ulcers and
that none of the patients in the famotidine group had gas-
troduodenal ulcers, 40 mg/day of famotidine may be as
effective as 15 mg/day of lansoprazole in the primary pre-
vention of LDA-related gastroduodenal ulcers. The pre-
ventive effects of 40 mg/day of famotidine vs. 15 mg/day
of lansoprazole on the development of LDA-related gas-
troduodenal ulcers require further investigation.
The clinical significance of gastroduodenal erosions in
patients taking LDA
The prevention of gastroduodenal erosions is considered
to be clinically important in patients taking LDA for the
following reasons. First, in patients taking LDA, some
gastroduodenal erosions may bleed. It has been shown
that in 16% to 23% of patients with upper gastrointes-
tinal bleeding, gastroduodenal erosions are the cause of
the bleeding [20,21]. Furthermore, gastric erosions have
been reported to be the second most common source of
gastrointestinal bleeding after acute myocardial infarc-
tion [22] in which the use of LDA is essential for
secondary prevention. Second, some gastroduodenal
erosions may develop into gastroduodenal ulcers in pa-
tients taking LDA. It has been reported that one-sixth of
gastroduodenal erosions become gastroduodenal ulcers
after 17 years [23]. Furthermore, the presence of gastro-
duodenal erosions has been reported to increase the risk
of developing gastroduodenal ulcers in nonsteroidal
anti-inflammatory drug users [24].
The strength and limitations of the present study
The strength of the present study is the sufficient sample
size to detect significant differences in the prevalence of
gastroduodenal erosions between the two groups. A post
hoc power determinant analysis showed that the present
study has an estimated power of 85% with a two-sided
alpha risk of 0.05. On the other hand, the present study
has a few limitations. First, this study had a cross-
sectional design, which could potentially carry a risk of
reverse causation. The duration of lansoprazole and
famotidine treatment was not identical between the two
groups. In addition, we did not investigate why either
40 mg/day of famotidine or 15 mg/day of lansoprazole
was selected for each patient. Therefore, prospective,
randomized, longitudinal studies are needed to clarify
whether 15 mg/day of lansoprazole is indeed more
effective in preventing LDA-related gastroduodenal ero-
sions than 40 mg/day of famotidine. Second, we did not
investigate the mechanisms of the lower prevalence of
gastroduodenal erosions observed in the lansoprazole
group. Third, larger doses of famotidine and lansoprazole
may be more effective in preventing LDA-related gastro-
duodenal erosions. Further investigations are required toclarify the associations between the doses of famotidine
and lansoprazole and their preventive effects on the devel-
opment of LDA-related gastroduodenal erosions.
Conclusion
The results of the present study suggest that 15 mg/day of
lansoprazole may be more effective in preventing LDA-
related gastroduodenal erosions than 40 mg/day of
famotidine. Elucidating the preventive effects of these two
regimens on the development of LDA-related gastroduo-
denal ulcers, however, still requires further investigation.
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